385 related articles for article (PubMed ID: 21515403)
1. Modulation of RXR function through ligand design.
Pérez E; Bourguet W; Gronemeyer H; de Lera AR
Biochim Biophys Acta; 2012 Jan; 1821(1):57-69. PubMed ID: 21515403
[TBL] [Abstract][Full Text] [Related]
2. Natural and Structure-based RXR Ligand Scaffolds and Their Functions.
Dominguez M; Alvarez S; de Lera AR
Curr Top Med Chem; 2017; 17(6):631-662. PubMed ID: 27320335
[TBL] [Abstract][Full Text] [Related]
3. Advances in drug design with RXR modulators.
Vaz B; de Lera ÁR
Expert Opin Drug Discov; 2012 Nov; 7(11):1003-16. PubMed ID: 22954251
[TBL] [Abstract][Full Text] [Related]
4. Ligand Design for Modulation of RXR Functions.
Martínez C; Souto JA; de Lera AR
Methods Mol Biol; 2019; 2019():51-72. PubMed ID: 31359388
[TBL] [Abstract][Full Text] [Related]
5. A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.
Kotani H; Tanabe H; Mizukami H; Amagaya S; Inoue M
Biol Pharm Bull; 2012; 35(1):1-9. PubMed ID: 22223330
[TBL] [Abstract][Full Text] [Related]
6. Structure basis of bigelovin as a selective RXR agonist with a distinct binding mode.
Zhang H; Li L; Chen L; Hu L; Jiang H; Shen X
J Mol Biol; 2011 Mar; 407(1):13-20. PubMed ID: 21262235
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.
Mukherjee R; Davies PJ; Crombie DL; Bischoff ED; Cesario RM; Jow L; Hamann LG; Boehm MF; Mondon CE; Nadzan AM; Paterniti JR; Heyman RA
Nature; 1997 Mar; 386(6623):407-10. PubMed ID: 9121558
[TBL] [Abstract][Full Text] [Related]
8. Retinoid X Receptor Selective Agonists and their Synthetic Methods.
Wagner CE; Jurutka PW; Marshall PA; Heck MC
Curr Top Med Chem; 2017; 17(6):742-767. PubMed ID: 27320333
[TBL] [Abstract][Full Text] [Related]
9. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death.
Ahuja HS; Szanto A; Nagy L; Davies PJ
J Biol Regul Homeost Agents; 2003; 17(1):29-45. PubMed ID: 12757020
[TBL] [Abstract][Full Text] [Related]
10. Modification at the acidic domain of RXR agonists has little effect on permissive RXR-heterodimer activation.
Fujii S; Ohsawa F; Yamada S; Shinozaki R; Fukai R; Makishima M; Enomoto S; Tai A; Kakuta H
Bioorg Med Chem Lett; 2010 Sep; 20(17):5139-42. PubMed ID: 20656484
[TBL] [Abstract][Full Text] [Related]
11. Retinoid X receptor ligands: a patent review (2007 - 2013).
Yamada S; Kakuta H
Expert Opin Ther Pat; 2014 Apr; 24(4):443-52. PubMed ID: 24456080
[TBL] [Abstract][Full Text] [Related]
12. RAR and RXR modulation in cancer and metabolic disease.
Altucci L; Leibowitz MD; Ogilvie KM; de Lera AR; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):793-810. PubMed ID: 17906642
[TBL] [Abstract][Full Text] [Related]
13. Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells.
Széles L; Póliska S; Nagy G; Szatmari I; Szanto A; Pap A; Lindstedt M; Santegoets SJ; Rühl R; Dezsö B; Nagy L
Mol Endocrinol; 2010 Nov; 24(11):2218-31. PubMed ID: 20861222
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies.
Pogenberg V; Guichou JF; Vivat-Hannah V; Kammerer S; Pérez E; Germain P; de Lera AR; Gronemeyer H; Royer CA; Bourguet W
J Biol Chem; 2005 Jan; 280(2):1625-33. PubMed ID: 15528208
[TBL] [Abstract][Full Text] [Related]
15. Biological characterization of a heterodimer-selective retinoid X receptor modulator: potential benefits for the treatment of type 2 diabetes.
Leibowitz MD; Ardecky RJ; Boehm MF; Broderick CL; Carfagna MA; Crombie DL; D'Arrigo J; Etgen GJ; Faul MM; Grese TA; Havel H; Hein NI; Heyman RA; Jolley D; Klausing K; Liu S; Mais DE; Mapes CM; Marschke KB; Michellys PY; Montrose-Rafizadeh C; Ogilvie KM; Pascual B; Rungta D; Tyhonas JS; Urcan MS; Wardlow M; Yumibe N; Reifel-Miller A
Endocrinology; 2006 Feb; 147(2):1044-53. PubMed ID: 16269450
[TBL] [Abstract][Full Text] [Related]
16. Retinoid X receptor agonists modulate Foxp3⁺ regulatory T cell and Th17 cell differentiation with differential dependence on retinoic acid receptor activation.
Takeuchi H; Yokota-Nakatsuma A; Ohoka Y; Kagechika H; Kato C; Song SY; Iwata M
J Immunol; 2013 Oct; 191(7):3725-33. PubMed ID: 23980207
[TBL] [Abstract][Full Text] [Related]
17. The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights.
Sato Y; Ramalanjaona N; Huet T; Potier N; Osz J; Antony P; Peluso-Iltis C; Poussin-Courmontagne P; Ennifar E; Mély Y; Dejaegere A; Moras D; Rochel N
PLoS One; 2010 Nov; 5(11):e15119. PubMed ID: 21152046
[TBL] [Abstract][Full Text] [Related]
18. The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo.
Cesario RM; Klausing K; Razzaghi H; Crombie D; Rungta D; Heyman RA; Lala DS
Mol Endocrinol; 2001 Aug; 15(8):1360-9. PubMed ID: 11463859
[TBL] [Abstract][Full Text] [Related]
19. Molecular determinants of the interactions between LXR/RXR heterodimers and TRAP220.
Son YL; Lee YC
Biochem Biophys Res Commun; 2009 Jul; 384(3):389-93. PubMed ID: 19410560
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a "Gatekeeper" Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers.
Watanabe M; Fujihara M; Motoyama T; Kawasaki M; Yamada S; Takamura Y; Ito S; Makishima M; Nakano S; Kakuta H
J Med Chem; 2021 Jan; 64(1):430-439. PubMed ID: 33356247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
